Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Online ahead of print]

11 C-choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large US Patient Series

Affiliations

11 C-choline PET/CT in Recurrent Prostate Cancer: Retrospective Analysis in a Large US Patient Series

Laure Michaud et al. J Nucl Med.

Abstract

Purpose: To evaluate 11C-choline PET/CT detection performance for biochemically recurrent prostate cancer (PCa) in a large non-European cohort in the context of emerging evidence for PSMA PET in this setting, and to map patterns of PCa recurrence. Methods: We retrospectively analyzed 11C-choline PET/CT scans from 287 patients who were enrolled onto an imaging protocol based on rising prostate-specific antigen (PSA) levels (mean:3.43 ng/mL, median:0.94 ng/mL, range:0.15-89.91) and suspected recurrent PCa. A total of 187 patients had undergone primary radical prostatectomy (RP; 79/187 had secondary radiotherapy), 30 had undergone primary radiotherapy (RT), and 70 had persistent PSA elevation after receiving initial treatment (69 post-RP, 1 post-RT). The level of suspicion for recurrence on 11C-choline PET/CT was scored (0:negative, 1:equivocal, 2:positive) by two readers. The correlation between 11C-choline PET/CT positivity and initial treatment, Gleason score, NCCN stage, PSA level, PSA doubling time, PSA velocity, and time between initial treatment and PET imaging was evaluated. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were used to map 11C-choline recurrence patterns. Results: Considering scores 1 and 2 as positives, consensus between the two readers deemed 66% of the 11C-choline PET/CT scans as positive. When sorted by PSA level, 45% of patients with PSA<0.5 ng/mL, 56% of patients with PSA 0.5-0.99 ng/mL, 70% of patients with PSA 1.0-1.99 ng/mL, and 90% of patients with PSA ≥2.0 ng/mL scored either 1 or 2 on 11C-choline PET/CT scans. When considering scores of 2 only, 11C-choline PET/CT positivity was 54% (28%, 46%, 62%, and 81%, respectively, for patients with PSA <0.5 ng/mL, 0.5-0.99 ng/mL, 1.0-1.99 ng/mL, and ≥2.0 ng/mL). In multivariate analysis, only the PSA level was significantly associated with scan positivity. Pattern analysis showed that pelvic lymph nodes were the most common site of recurrence, and 28% of patients had 11C-choline-positive suspected recurrences outside the initial treatment field. Conclusion: 11C-choline PET/CT can detect PCa recurrence even among patients with low PSA levels when interpretation accounts for the clinical context, providing a certain pre-test probability. Until PSMA agents are fully approved for PCa, choline PET/CT may provide clinical utility.

Keywords: 11C-choline PET/CT; Molecular Imaging; Oncology: GU; PET/CT; PSA relapse; prostate cancer; prostate-specific antigen; recurrence.

Similar articles

See all similar articles

LinkOut - more resources

Feedback